SKYE

Skye Bioscience, Inc. (SKYE) SWOT Analysis Analysis (2026)

Invetso Score: 6.2/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 8.4 (Strong)

ROIC of 112.4% indicates unusually efficient capital deployment versus peers, supporting superior value creation even if operating and gross margins are not disclosed.

Net debt to EBITDA of 0.16x suggests a lighter leverage burden than many peers, which preserves financial flexibility and reduces refinancing pressure.

A current and quick ratio of 0.95x is near parity with short-term obligations, implying working-capital discipline relative to weaker liquidity profiles.

The reported cash conversion cycle is deeply negative, indicating cash is collected before it is paid out and creating a structural working-capital advantage versus peers.

Weaknesses

Score:

Current and quick ratios below 1.0x indicate limited liquidity headroom, leaving the company less resilient than peers with stronger near-term balance sheets.

The absence of disclosed operating and gross margins limits visibility into core profitability, making peer comparison harder and weakening the quality of the operating profile assessment.

Negative debt-to-equity likely reflects an atypical equity base rather than a clear strength, which can complicate capital-structure comparability versus peers.

The extreme cash conversion cycle figure may reflect accounting or business-model distortions, reducing confidence in its comparability to peer working-capital metrics.

Opportunities

Score:

If the company sustains its capital efficiency, peers with lower ROIC would face a widening valuation and reinvestment gap over the next two to five years.

Further balance-sheet normalization could improve liquidity metrics, allowing SKYE to compare more favorably with peers that already maintain stronger current ratios.

Greater disclosure of segment economics and margin structure would improve market visibility, potentially narrowing the information gap versus better-covered peers.

Any conversion of working-capital efficiency into recurring free cash flow could strengthen competitive positioning against peers with more capital-intensive operating models.

Threats

Score:

Peers with stronger liquidity buffers can absorb demand shocks more easily, while SKYE’s sub-1.0x current ratio leaves less room for operational volatility.

If the reported ROIC is driven by a small equity base or non-recurring factors, peer-relative capital efficiency could normalize downward over time.

Limited margin disclosure increases the risk that peers with clearer profitability profiles are perceived as structurally stronger by investors and counterparties.

The unusually negative cash conversion cycle may prove less durable than it appears, which would erode a key peer-relative working-capital advantage.

Overall Score

Score:

SKYE’s peer-relative positioning is supported by exceptional capital efficiency and low leverage, but weaker liquidity and limited operating disclosure keep the overall profile moderate.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Skye Bioscience, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →